1P50 Stock Overview
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PAVmed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.18 |
| 52 Week High | US$7.50 |
| 52 Week Low | US$2.73 |
| Beta | 0.85 |
| 1 Month Change | 0% |
| 3 Month Change | -20.90% |
| 1 Year Change | -44.79% |
| 3 Year Change | -93.12% |
| 5 Year Change | n/a |
| Change since IPO | -94.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1P50 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | -1.0% |
| 1Y | -44.8% | -10.8% | 2.0% |
Return vs Industry: 1P50 underperformed the German Medical Equipment industry which returned 5% over the past year.
Return vs Market: 1P50 underperformed the German Market which returned 1% over the past year.
Price Volatility
| 1P50 volatility | |
|---|---|
| 1P50 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1P50's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 1P50's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 124 | Lishan Aklog | www.pavmed.com |
PAVmed Inc. operates as a medical device company in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett’s Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform.
PAVmed Inc. Fundamentals Summary
| 1P50 fundamental statistics | |
|---|---|
| Market cap | €20.36m |
| Earnings (TTM) | -€65.42m |
| Revenue (TTM) | €1.40m |
14.6x
P/S Ratio-0.3x
P/E RatioIs 1P50 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1P50 income statement (TTM) | |
|---|---|
| Revenue | US$1.52m |
| Cost of Revenue | US$6.43m |
| Gross Profit | -US$4.91m |
| Other Expenses | US$65.99m |
| Earnings | -US$70.90m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.81 |
| Gross Margin | -324.22% |
| Net Profit Margin | -4,679.67% |
| Debt/Equity Ratio | -284.2% |
How did 1P50 perform over the long term?
See historical performance and comparison